National Alliance on Mental Illness

RESEARCH OPPORTUNITY

NAMI is committed to improving the lives of people impacted by mental health conditions through effective treatments, equitable public policies, and greater knowledge and understanding in society. Research is essential to advance each of these goals. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting research participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these studies.

If you have questions about research at NAMI, please visit NAMI.org/research or email research@nami.org.

WHAT IS THE STUDY?

This study is a clinical trial that investigates the genetic factors that contribute to major depressive disorder (MDD) and bipolar disorder, and how genetic factors can contribute to patient response to Electroconvulsive Therapy (ECT). Participation involves a one-time collection of a blood or saliva sample (at a study site or using an at-home kit) along with consenting to access of medical records. Upon completion of the informed consent form and biospecimen collection, participants will receive compensation and reimbursement for transportation costs. The goal of this study is to learn whether we can predict, based on genetics, which individuals diagnosed with MDD, and bipolar disorder will respond well to ECT versus who will respond poorly or have adverse effects from ECT.

WHO CAN PARTICIPATE?

Participants may be eligible for this study if they:

- Are aged 18 or older and have a primary lifetime diagnosis of MDD or bipolar disorder
- Are currently receiving ECT; or
- Have received ECT in the past; or
- Are/were a candidate for ECT but declined or opted for another non-first line treatment, such as repetitive transcranial magnetic stimulation or IV/IN ketamine; or

The researchers are seeking 15,000 people for this study.

WHERE IS THE STUDY TAKING PLACE?

There are multiple study sites located across the U.S. Remote participation is also possible.

HOW DO I LEARN MORE?

The documents attached have additional information about the study. If you have questions or would like more information, please visit genectstudy.com or contact the researchers at jhmood@jh.edu.